Download our eBook, Spark Therapeutics: The journey of a gene therapy company from spinout to big pharma acquisition

What does it take for a life science company with a breakthrough therapy to have a successful exit? Spark Therapeutics offers up an interesting example.

When Spark secured FDA approval for Luxturna, it was the first for a gene therapy targeting a disease caused by a single faulty gene. The one-time treatment for adults and children also filled an unmet need for a form of inherited retinal degeneration that can lead to progressive vision loss and blindness.

MedCity News reporters have tracked the progress of Spark since the Philadelphia-based business spun out of Children’s Hospital of Philadelphia Center for Cellular & Molecular Therapeutics and all the way through its acquisition by Roche this year.